WebAug 7, 2024 · Freeline Therapeutics was founded in 2015 by UCLB, the commercialisation arm of UCL and part of UCL Innovation & Enterprise, and Syncona LLP. The company has received significant funding from the UCL Technology Fund (managed by AlbionVC in collaboration with UCLB). WebDec 19, 2024 · Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces Syncona Ltd (“Syncona) has …
Syncona invests $80m in Freeline’s systemic disease gene therapies
WebMar 11, 2024 · Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV … WebDec 19, 2024 · Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces Syncona Ltd (Syncona) has made an $80.0 million (£61.1 million)[1] commitment in a Series C financing and has funded the first tranche of this commitment, amounting to $40.0 million (£30.6 million)[2]. can help myself art
Investors Syncona
WebJan 27, 2024 · LONDON, January 27, 2024 - Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster … WebFeb 4, 2024 · Syncona has a 79 percent holding in Freeline. Syncona also said it led a 32.0 million pounds Series B financing in Azeria Therapeutics, with a 29.5 million pounds … WebOct 6, 2024 · UCL spinout Freeline Therapeutics is taking groundbreaking gene research from UCL, with the aim of developing it into a potentially life-changing treatment for people with haemophilia B. ... Syncona invested £25 million into Freeline in 2016, alongside the UCL Technology Fund. can help ontario